BioCentury
ARTICLE | Company News

GTx, Orion Group deal

December 20, 2004 8:00 AM UTC

GTXI purchased expanded rights to toremifene from Orion for about $5.2 million. The expansion gives GTXI exclusive rights to toremifene for all U.S. indications and worldwide rights for all indication...